Scientists probe fat and blood molecules to unlock new diabetes treatments

NCT ID NCT06955130

Not yet recruiting Knowledge-focused Sponsor: Rutgers, The State University of New Jersey Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study investigates how two molecules—glycerol from fat and lactate from the blood—are converted into glucose by the liver, especially in people with type 2 diabetes. Researchers will compare these processes in 48 adults with and without diabetes or obesity. Participants receive infusions of glycerol, lactate, and glucose along with glucagon, and blood samples are analyzed to track carbon flow. The goal is to identify new drug targets for lowering blood glucose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Glycerol, Lactate, Glucose
What this could lead to: If successful, this research could point toward new drug targets that lower blood glucose more effectively in type 2 diabetes.
What could go wrong: This is an early-stage observational study with only 48 participants. It measures metabolic processes, not treatment outcomes, so direct benefits are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus Obesity obesity disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY OBESITY TYPE 2 DIABETES

More trials for these conditions

Other studies related to the condition(s) this trial covers.